Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report

about

Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report

Item

http://www.wikidata.org/entity/Q59127261

description

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Successful response to the com ...... D-L1 expression: a case report

@en

Successful response to the com ...... D-L1 expression: a case report

@nl

type

Item

label

Successful response to the com ...... D-L1 expression: a case report

@en

Successful response to the com ...... D-L1 expression: a case report

@nl

prefLabel

Successful response to the com ...... D-L1 expression: a case report

@en

Successful response to the com ...... D-L1 expression: a case report

@nl

P1476

Successful response to the com ...... D-L1 expression: a case report

@en

P2093

Haibo Mou

http://www.w3.org/2001/XMLSchema#string

Kai Wang

http://www.w3.org/2001/XMLSchema#string

Lanfang Yu

http://www.w3.org/2001/XMLSchema#string

Lingjian Wang

http://www.w3.org/2001/XMLSchema#string

Ming Yao

http://www.w3.org/2001/XMLSchema#string

Na Yan

http://www.w3.org/2001/XMLSchema#string

Qiang Cui

http://www.w3.org/2001/XMLSchema#string

Qin Liao

http://www.w3.org/2001/XMLSchema#string

Ruobing Ma

http://www.w3.org/2001/XMLSchema#string

Xuehua Hou

http://www.w3.org/2001/XMLSchema#string

P2860

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Lymph node metastasis in intrahepatic cholangiocarcinoma.

Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study.

"Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention.

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.

The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.

Cancer immunotherapies targeting the PD-1 signaling pathway.

P2888

s12885-018-5021-2

P304

1105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S12885-018-5021-2

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1109820478

http://www.w3.org/2001/XMLSchema#string

P698

30419854

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

chemotherapy

P932

6233589

http://www.w3.org/2001/XMLSchema#string